plasma care® celebrates product launch in Taiwan
plasma care receives market approval from the TFDA in Taiwan and is now exclusively distributed by Omega Medical in Taiwan.
plasma care receives market approval from the TFDA in Taiwan and is now exclusively distributed by Omega Medical in Taiwan.
As Managing Director, Lukas Herbert will work with Jens Kirsch to drive forward the expansion and internationalization of the company.
terraplasma medical announces marketing authorisation and market launch of plasma care® in Brazil.
Investigation of the effect of topical non-invasive physical plasma on the prevention of acute radiation dermatitis.
The international expansion of terraplasma medical GmbH, a subsidiary of the Viromed Group, is progressing. The strategic mainstay is the innovative treatment of wounds based on cold atmospheric plasma (KAP). The focus is on the mobile, CE-certified cold plasma device plasma care®, which closes wounds painlessly and inactivates viruses, fungi and bacteria.
With over 600 speakers and almost 16,000 participants, the annual EADV congress is Europe's most important event in the field of dermatology and venereology. From October 11 to 14, we…
There is a solution for people with chronic and non-healing wounds: cold atmospheric plasma (KAP). As a pilot study commissioned by Munich-based terraplasma medical GmbH, a company of the Hamburg-based Viromed Group, proves, the innovative wound and skin treatment of the cold plasma technique is superior to standard wound treatment (SWT).
The three leading companies neoplas med GmbH, terraplasma-medical GmbH and Cinogy System GmbH are forming a consortium to commission the trial study in the method evaluation procedure of the Federal Joint Committee (G-BA).
GD Medical becomes exclusive distributor for the benelux region.
While patients with chronic wounds in Germany and other parts of Europe have been able to benefit from the effect of cold atmospheric plasma for some time now, medical cold…